Laboratorios Farmaceúticos Rovi SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: ES0157261019
EUR
78.90
62.35 (376.74%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With ROE of 21.13%, it has a Very Expensive valuation with a 6.09 Price to Book Value

  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 51.88%, its profits have risen by 2.6% ; the PEG ratio of the company is 11.2
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 3,996 Million ()

stock-summary
P/E

29.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

126.39%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

21.13%

stock-summary
Price to Book

6.01

Revenue and Profits:
Net Sales:
218 Million
(Quarterly Results - Dec 2025)
Net Profit:
43 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
376.74%
0%
376.74%
6 Months
376.74%
0%
376.74%
1 Year
376.74%
0%
376.74%
2 Years
376.74%
0%
376.74%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Laboratorios Farmaceúticos Rovi SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
12.10%
EBIT Growth (5y)
18.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.12
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
1.34
Tax Ratio
22.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
36.67%
ROE (avg)
28.59%

Valuation key factors

Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
6.09
EV to EBIT
23.46
EV to EBITDA
19.96
EV to Capital Employed
5.98
EV to Sales
5.46
PEG Ratio
11.18
Dividend Yield
124.79%
ROCE (Latest)
25.50%
ROE (Latest)
21.13%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 9.69% vs -15.13% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 82.48% vs -54.56% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "218.40",
          "val2": "199.10",
          "chgp": "9.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.10",
          "val2": "39.80",
          "chgp": "58.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.70",
          "chgp": "14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.70",
          "val2": "23.40",
          "chgp": "82.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "251.50%",
          "val2": "162.50%",
          "chgp": "8.90%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2.65% vs -7.93% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 2.56% vs -19.61% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "743.50",
          "val2": "763.70",
          "chgp": "-2.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "203.50",
          "val2": "206.70",
          "chgp": "-1.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.80",
          "val2": "2.40",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "140.40",
          "val2": "136.90",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "232.90%",
          "val2": "234.00%",
          "chgp": "-0.11%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
218.40
199.10
9.69%
Operating Profit (PBDIT) excl Other Income
63.10
39.80
58.54%
Interest
0.80
0.70
14.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
42.70
23.40
82.48%
Operating Profit Margin (Excl OI)
251.50%
162.50%
8.90%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 9.69% vs -15.13% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 82.48% vs -54.56% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
743.50
763.70
-2.65%
Operating Profit (PBDIT) excl Other Income
203.50
206.70
-1.55%
Interest
2.80
2.40
16.67%
Exceptional Items
-0.10
0.00
Consolidate Net Profit
140.40
136.90
2.56%
Operating Profit Margin (Excl OI)
232.90%
234.00%
-0.11%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -2.65% vs -7.93% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 2.56% vs -19.61% in Dec 2024

stock-summaryCompany CV
About Laboratorios Farmaceúticos Rovi SA stock-summary
stock-summary
Laboratorios Farmaceúticos Rovi SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available